Open Access

SGLT2 inhibitors: optimising heart failure treatment

Event: Heart Failure 2021 Online Congress
Topic: Chronic Heart Failure, Other
Session type: Satellite Symposium
Sponsored by AstraZeneca
Date: 1 July 2021
Time: 16:05 - 16:35

Congress Session

This content is currently on OPEN ACCESS

Sign in to view the resources

3 presentations in this session

Welcome and introductions Optimising patient outcomes: A guide to the initiation of SGLT2 inhibitors from first-hand experience.

Speaker: Professor G. Fonarow (Los Angeles, US)

Considerations for therapy optimisation.

Speaker: Professor C. Lam (Singapore, SG)

2 speakers from this session

Professor Gregg Fonarow

UCLA MEDICAL CENTER CARDIOLOGY, Los Angeles (United States of America)
1 presentation
0 follower

Professor Carolyn Sp Lam

Duke-NUS Graduate Medical School Singapore, Singapore (Singapore)
102 presentations

Related content

ESC Premium Access

ESC Guidelines 2021 - Heart Failure

3 December 2021

ESC Premium Access

Evolving role of SGLT2i in HFrEF management

3 December 2021

ESC Premium Access

Update on endocarditis in 2021

3 December 2021

This platform is supported by

logo Novo Nordisk